Thermo Fisher Scientific Inc. has announced that it has established a grant program to award life science researchers more than $400,000 in RNA-interference (RNAi) reagents used to study genes in medical research and drug discovery.
The Thermo Scientific Discovery Grant Program will include various siRNA, shRNA and microRNA reagents from the industry-leading Dharmacon and Open Biosystems RNAi technology portfolios, marketed under the Thermo Scientific brand. Five projects will be selected based on their potential to advance science and medicine.
Recent breakthroughs involving Thermo Scientific RNAi technologies include a study to find human genes associated with West Nile virus infection, the discovery of potential new targets for HIV drugs and identification of genes that appear to affect the susceptibility of human cancer cells to certain chemotherapy treatments.
“Thermo Fisher is a world leader in providing tools for gene analysis, and we have led the way in the use of RNAi technologies for scientific research,” said Marc N. Casper, chief operating officer of Thermo Fisher Scientific. “We have created this grant program to advance RNAi-based screening and to help our life sciences customers accelerate their discoveries.”
The Thermo Scientific RNAi Discovery Grant Program is open to both academic and commercial researchers, who may complete a simple application online at www.thermo.com/RNAiDiscovery.
Grant applications will be reviewed by a panel of scientists at Thermo Fisher Scientific, and recipients will be selected based on the merit of their projects, their screening capabilities and, most importantly, potential scientific impact. Applications for the grants will be accepted through September 7, 2009.